



September 22, 2021

Ms. Odalys Caprisecca
Executive Director, US Strategic Price & Operations
AstraZeneca Pharmaceuticals, LP
1800 Concord Pike
Wilmington, Delaware 19803

Dear Ms. Caprisecca:

By letter dated May 17, 2021, HRSA instructed AstraZeneca Pharmaceuticals, LP (AstraZeneca) to comply with its 340B statutory obligations and to immediately begin offering AstraZeneca's covered outpatient drugs at the 340B ceiling price to covered entities that dispense the discounted medications through their contract pharmacy arrangements. HRSA informed AstraZeneca that continued failure to provide the 340B price to covered entities utilizing contract pharmacies could result in civil monetary penalties.

Given AstraZeneca's continued refusal to comply,¹ HRSA has referred this issue to the HHS Office of the Inspector General (OIG) in accordance with the 340B Program Ceiling Price and Civil Monetary Penalties Final Rule.²

Sincerely,

/Michelle Herzog/

Michelle Herzog
Acting Director
Office of Pharmacy Affairs

¹ AstraZeneca provided HRSA its basis for refusing to comply in a letter dated June 10, 2021.

² 82 Fed. Reg. 1210, 1230 (Jan. 5, 2017); 42 C.F.R. § 10.11(a)